Palvella Therapeutics expands its Phase 3 trial to include younger patients for potential microcystic LMs treatment.
Quiver AI Summary
Palvella Therapeutics has announced the expansion of its Phase 3 SELVA clinical trial to include younger patients, specifically those aged 3 to 5, in the evaluation of QTORIN™ rapamycin for treating microcystic lymphatic malformations. This decision follows favorable communication with the FDA, which has granted multiple designations to QTORIN™ rapamycin, potentially laying the groundwork for it to become the first approved therapy for this condition in the U.S. The trial aims to enroll around 40 participants and focuses on addressing the serious complications associated with microcystic LMs, a genetic disease characterized by malformed lymphatic vessels. The expansion stresses the importance of early intervention in managing this chronic and progressively debilitating condition.
Potential Positives
- Palvella's expansion of the SELVA clinical trial to include patients aged 3 to 5 years old demonstrates a commitment to addressing the needs of younger patients suffering from microcystic LMs, which enhances the potential market for QTORIN™ rapamycin.
- The FDA's acceptance of Palvella's proposed expansion showcases regulatory support, which can enhance the credibility and attractiveness of the company's clinical research efforts.
- QTORIN™ rapamycin holds the potential to be the first approved therapy in the U.S. for microcystic LMs, indicating significant first-mover advantages in a market with no current FDA-approved treatments.
- Receiving multiple designations from the FDA—including Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation—highlights the drug's promising therapeutic potential and accelerates development and review processes.
Potential Negatives
- Expansion of the clinical trial to a younger age group may indicate difficulties meeting enrollment targets with the previous age criteria.
- The press release emphasizes that there are currently no FDA-approved therapies for microcystic LMs, highlighting the unmet need and potential risk of prolonged development timelines for QTORIN™ rapamycin.
- Forward-looking statements showcase significant reliance on future successes and fundraising, indicating potential financial instability if projected results are not met.
FAQ
What is the purpose of the SELVA clinical trial?
The SELVA trial evaluates QTORIN™ rapamycin for treating microcystic lymphatic malformations in patients.
Who is eligible for the SELVA trial?
Patients ages 3 to 5 years old can now participate, expanding from the previous requirement of being at least 6 years old.
What designation has the FDA granted to QTORIN™ rapamycin?
The FDA has granted QTORIN™ rapamycin Breakthrough Therapy, Fast Track, and Orphan Drug Designations for microcystic LMs.
How common are microcystic lymphatic malformations?
Microcystic LMs are rare, affecting an estimated 30,000 patients in the United States.
What is the expected timeline for trial results?
Palvella plans to report top-line results from the SELVA trial in Q1 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PVLA Insider Trading Activity
$PVLA insiders have traded $PVLA stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PVLA stock by insiders over the last 6 months:
- GEORGE M JENKINS purchased 4,000 shares for an estimated $51,720
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
Expansion reflects Palvella's commitment to serving all patients affected
by microcystic lymphatic malformations (microcystic LMs)
Company remains on track to report top line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of microcystic LMs, in Q1 2026
QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs
WAYNE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA)
Palvella Therapeutics, Inc.
(Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will expand SELVA, the Company's Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), to include patients ages 3 to 5 years old. Previously, trial participants were required to be at least 6 years old. This decision follows communication with the U.S. Food and Drug Administration (FDA) in which the agency deemed the Company's proposed expansion acceptable.
“Microcystic LMs is a debilitating disease that is chronic, progressive, and usually present at birth or shortly after. Patients with microcystic LMs often have lymphorrhea, bleeding, infection, pain, and disfigurement which may lead to difficulty with physical activities as well as more significant complications like cellulitis and hospitalization,” said Joyce Teng MD, PhD, Professor of Dermatology and Pediatrics at Stanford University and Principal Investigator of the SELVA Study. “Early intervention is essential to minimize disease burden during children’s development which is why I am so excited by the opportunity QTORIN rapamycin presents to the younger pediatric population.”
Palvella is currently enrolling approximately 40 patients in SELVA, a 24-week, Phase 3, single-arm, baseline-controlled trial of QTORIN™ rapamycin for the treatment of microcystic LMs. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation to QTORIN™ rapamycin for the treatment of microcystic LMs. Additionally, the SELVA study is supported by an Orphan Products Grant of up to $2.6 million from FDA’s Office of Orphan Products Development.
About Microcystic Lymphatic Malformations
Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. The disease is characterized by malformed lymphatic vessels that protrude through the skin and persistently leak lymph fluid (lymphorrhea) and bleed, often leading to recurrent serious infections and cellulitis that can cause hospitalization. The natural history of microcystic LMs is persistent and progressive without spontaneous resolution, with symptoms generally worsening during life, including increases in the number and size of malformed vessels that lead to complications and lifetime morbidity. There are currently no FDA-approved treatments for the estimated more than 30,000 diagnosed patients with microcystic LMs in the United States.
About Palvella Therapeutics
Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit
www.palvellatx.com
or follow Palvella on
LinkedIn
or
X
(formerly known as Twitter).
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the potential of, and expectations regarding, Palvella’s programs, including QTORIN™ rapamycin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the “Risk Factors” section of Palvella’s registration statement on Form S-1 filed with the Securities and Exchange Commission on December 31, 2024 and other documents filed by Palvella from time to time with the Securities Exchange Commission. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.
kaupinen@palvellatx.com
Media
Stephanie Jacobson
Managing Director, Argot Partners
palvella@argotpartners.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
